MRK

Merck & Co.
Pharmaceuticals · Health Care · as of 2026-11-20
Last close
$134.56
+1.3% on the session
1-year return
+45.8%
+11.4% over six months
Volatility
30.2%
annualized, trailing year
Max drawdown
-14.6%
worst peak to trough, 1y
What the numbers say

Merck & Co. is a pharmaceuticals name in the health care sector. Over the past year it returned +45.8%, against -10.2% over three months and -8.6% over one. It sits just 5.0% above its 200-day average, technically in an uptrend, but without much room. Annualized volatility of 30.2% is above the market's typical range.

Its worst peak-to-trough decline over the year was -14.6%, and it has traded a median $1.3B a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.13 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#39 of 59
Stronger than 34% of its sector on the momentum profile
Across the whole index#166 of 497

How MRK scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 6 others in Pharmaceuticals.

Start a free 7-day trial
Full metrics
1 day+1.3%
1 week-8.9%
1 month-8.6%
3 months-10.2%
6 months+11.4%
1 year+45.8%
12-1 momentum+59.5%
Volatility (1y, annualized)30.2%
Max drawdown (1y)-14.6%
Distance vs 200-day average+5.0%
Return per unit of risk1.52
Median daily dollar volume$1.3B
Free newsletter

Get MRK when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.